CRBP

Corbus Pharmaceuticals Holdings Inc

5.85

Oct 05 • 3:59 PM ET -0.28 (-4.57%)

5.85

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: OABI CAMP RNA TNXP UNCY KPTI CNTX ELTX TENX ENLV

| Held by: VTI IWM VXF VTWO IWN FESM DFAS IWC DFMC VTWV

Scroll to Statements

Index	RUT
Market Cap	113.14M
Enterprise Value	-0.54M
Income	-101.90M
Sales	0.00M
Book/sh	5.48
Cash/sh	6.10
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	36
IPO	Oct 27, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.07
P/C	0.96
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	5.71
Current Ratio	5.71
Debt/Eq	0.04
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	-6.18
EPS next Y	-5.51
EPS next Q	-1.21
EPS this Y	7.89%
EPS next Y	-1.46%
EPS next 5Y	1.30%
EPS past 3/5Y	16.56% 32.70%
Sales past 3/5Y	- -
EPS Y/Y TTM	-29.66%
Sales Y/Y TTM	-
EPS Q/Q	-25.12%
Sales Q/Q	-
Earnings	Aug 06 BMO
EPS/Sales Surpr.	-43.79% -

Insider Own	10.22%
Insider Trans	-1.21%
Inst Own	73.00%
Inst Trans	4.51%
ROA	-80.85%
ROE	-95.58%
ROIC	-96.59%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-21.67%
SMA50	-35.50%
SMA200	-34.70%
Trades

Shs Outstand	18.67M
Shs Float	17.36M
Short Float	15.89%
Short Ratio	3.85
Short Interest	2.76M
52W High	20.56 -71.55%
52W Low	6.06 -3.47%
Volatility	7.38% 8.67%
ATR (14)	0.57
RSI (14)	24.33
Beta	2.75
Rel Volume	1.11
Avg Volume	716.54K
Volume	793,491

Perf Week	-15.46%
Perf Month	-48.95%
Perf Quarter	-37.63%
Perf Half Y	-42.31%
Perf YTD	-28.13%
Perf Year	-60.55%
Perf 3Y	-9.72%
Perf 5Y	-81.07%
Perf 10Y	-97.80%
Recom	1.00
Target Price	34.02
Prev Close	6.13
Price	5.85
Change %	-4.57%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-29-26	Initiated	Guggenheim	Buy	$45
Jul-30-25	Resumed	B. Riley Securities	Buy	$28
Feb-28-25	Initiated	William Blair	Outperform
Dec-02-24	Initiated	Piper Sandler	Overweight
Jul-30-24	Initiated	Wedbush	Outperform	$85
Jul-22-24	Resumed	H.C. Wainwright	Buy	$80
Jun-26-24	Initiated	B. Riley Securities	Buy	$85
Jun-03-24	Reiterated	Oppenheimer	Outperform	$60 → $80
May-13-24	Initiated	RBC Capital Mkts	Outperform	$77
Mar-06-24	Upgrade	Jefferies	Hold → Buy	$4 → $46
Sep-08-20	Downgrade	ROTH Capital	Buy → Neutral	$40 → $3
Sep-08-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-08-20	Downgrade	Jefferies	Buy → Hold	$18 → $2.50
Sep-08-20	Downgrade	BTIG Research	Buy → Neutral
Jul-07-20	Initiated	ROTH Capital	Buy	$40
Jun-17-20	Initiated	BTIG Research	Buy	$22
Mar-26-20	Initiated	Nomura	Buy	$12
Apr-05-19	Initiated	Jefferies	Buy
Mar-20-19	Initiated	Oppenheimer	Outperform	$28
Jan-11-19	Reiterated	Cantor Fitzgerald	Overweight	$36 → $38

Show Previous Ratings

Sep-29-26 08:00AM	Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer (GlobeNewswire)
Sep-14-26 09:28AM	Corbus Pharmaceuticals Shares Rise 12% After CANYON-1 Obesity Trial Data (InvestorsHub)
07:00AM	Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity (GlobeNewswire)
Sep-11-26 04:01PM	Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity (GlobeNewswire)
Aug-17-26 10:00AM	Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:12AM	Loading…
Aug-06-26 08:12AM	Corbus Pharmaceuticals: Q2 Earnings Snapshot (Associated Press)
08:00AM	Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update (GlobeNewswire)
Aug-04-26 08:30AM	Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity (GlobeNewswire) +5.38%
Jul-28-26 08:00AM	Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer (GlobeNewswire)
Jul-06-26 08:00AM	Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer (GlobeNewswire)
May-26-26 07:00AM	Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers (GlobeNewswire) -30.31%
May-21-26 08:00AM	Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call (GlobeNewswire) +18.29%
May-14-26 08:00AM	Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors (GlobeNewswire)
May-13-26 07:00AM	Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.30%
May-12-26 08:06AM	Corbus Pharmaceuticals: Q1 Earnings Snapshot (Associated Press)
08:00AM	Loading…
08:00AM	Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update (GlobeNewswire)
May-05-26 08:00AM	Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026 (GlobeNewswire)
Apr-29-26 09:42AM	Spotify upgraded, Alibaba initiated: Wall Street's top analyst calls (The Fly)
Apr-22-26 08:00AM	Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701 (GlobeNewswire)
Apr-14-26 08:00AM	Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity (GlobeNewswire)
Apr-07-26 08:00AM	Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer (GlobeNewswire)
Mar-18-26 08:00AM	Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit (GlobeNewswire) -6.02%
Mar-09-26 07:48AM	Corbus Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance) +19.23%
07:30AM	Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-26-26 03:08AM	Corbus Pharmaceuticals Touts Catalyst-Rich 2026 With CRB-701 and CRB-913 Data Readouts Ahead (MarketBeat) +6.18%
Feb-12-26 08:00AM	Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference (GlobeNewswire)
Jan-05-26 07:30AM	Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-25 11:16AM	2 Pharma Stocks Pop on Strong Obesity Drug Trial Results (Schaeffer's Research) -5.65%
07:00AM	Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss (GlobeNewswire)
Dec-10-25 04:01PM	Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025 (GlobeNewswire)
08:09AM	Loading…
Nov-12-25 08:09AM	Corbus Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance) +7.39%
08:00AM	Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-06-25 08:00AM	Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-31-25 02:40AM	Corbus Pharmaceuticals Announces Pricing of Public Offering (GlobeNewswire) -26.09%
Oct-30-25 04:31PM	Corbus Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire)
Oct-18-25 03:00AM	Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25 (GlobeNewswire)
Oct-14-25 08:00AM	Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025 (GlobeNewswire)
Oct-07-25 08:00AM	Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium (GlobeNewswire)
Sep-22-25 08:00AM	Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025 (GlobeNewswire)
Sep-16-25 08:00AM	FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma (GlobeNewswire) +9.61%
Aug-08-25 10:15AM	Can Cannabis Stocks Reverse Their Prolonged Downtrend? (Zacks) -6.33%
Aug-05-25 08:11AM	Corbus Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-30-25 08:00AM	Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress (GlobeNewswire)
Jun-30-25 08:00AM	Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity (GlobeNewswire) -6.76%
Jun-25-25 08:00AM	Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab (GlobeNewswire) +8.92%
Jun-24-25 04:05PM	Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium (GlobeNewswire)
May-23-25 11:13AM	3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies (Zacks)
May-22-25 08:00AM	Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-19-25 08:00AM	Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair (GlobeNewswire) +5.72%
May-16-25 07:48AM	Is Small-Cap Corbus Pharma a Worthy Cannabis Investment? (Zacks)
May-08-25 08:00AM	Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference (GlobeNewswire) +8.48%
07:20AM	Cannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold? (Zacks)
May-06-25 08:08AM	Corbus Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance) -15.77%
08:00AM	Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-29-25 08:14AM	3 Unconventional Cannabis Stocks to Watch in 2025 (Zacks)
Apr-18-25 09:55AM	Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High? (Zacks)
Mar-28-25 08:00AM	Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity (GlobeNewswire)
Mar-20-25 09:35AM	After Plunging -22.69% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP) (Zacks)
Mar-19-25 09:35AM	After Plunging -22.9% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP) (Zacks)
Mar-13-25 12:00PM	Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's What You Should Know (Zacks) -7.09%
Mar-11-25 08:17AM	Corbus Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-25-25 08:00AM	Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-14-25 01:17PM	Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate (Benzinga) -10.23%
07:30AM	CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025 (GlobeNewswire)
Feb-11-25 07:30AM	Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU (GlobeNewswire) -10.22%
Jan-28-25 08:00AM	Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-08-25 08:00AM	Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025 (GlobeNewswire)
Jan-06-25 08:00AM	Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-09-24 07:00AM	Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors (GlobeNewswire)
Dec-04-24 12:31PM	Why Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Dec-03-24 07:00AM	FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer (GlobeNewswire) -6.11%
Nov-26-24 06:54AM	Corbus Pharmaceuticals Holdings, Inc. (CRBP): An Oversold Healthcare Stock to Invest In Now (Insider Monkey)
Nov-21-24 08:00AM	Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference (GlobeNewswire)
Nov-12-24 08:00AM	Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-07-24 07:28AM	Corbus Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-04-24 04:10PM	Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat (Investor's Business Daily) +8.22%
07:00AM	Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024 (GlobeNewswire)
Oct-29-24 08:00AM	Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference (GlobeNewswire)
Oct-16-24 08:00AM	Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701) (GlobeNewswire)
Oct-15-24 07:02PM	Millennium Management LLC Adjusts Stake in Corbus Pharmaceuticals (GuruFocus.com)
Oct-11-24 07:02PM	Octagon Capital Advisors LP Increases Stake in Corbus Pharmaceuticals Holdings Inc (GuruFocus.com)
Oct-03-24 05:07AM	Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) the Best Russell 2000 Stock to Buy According to Analysts? (Insider Monkey)
Sep-26-24 08:00AM	Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit (GlobeNewswire)
Sep-24-24 09:41PM	Cormorant Asset Management's Strategic Acquisition in Corbus Pharmaceuticals (GuruFocus.com) +16.41%
Sep-20-24 03:18PM	Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players (Benzinga) -62.26%
Sep-12-24 07:59AM	Transforming Cancer Therapy Stocks to Watch In The Oncology Sector (News Direct)
Sep-05-24 08:00AM	Corbus Pharmaceuticals to Present at the 2024 Cantor Global Health Conference (GlobeNewswire) -8.32%
Sep-04-24 07:29PM	Corbus Pharmaceuticals Holdings, Inc. (CRBP): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-27-24 08:03PM	Corbus Pharmaceuticals Holdings, Inc. (CRBP): One of Oppenheimers Top Stock Picks For the Next 12 Months (Insider Monkey)
Aug-26-24 09:55AM	Wall Street Analysts Think Corbus Pharmaceuticals (CRBP) Could Surge 43.82%: Read This Before Placing a Bet (Zacks)
Aug-21-24 05:00AM	The Future of Medicine: Key Biotech Stocks to Watch (News Direct) +7.45%
Aug-20-24 08:00AM	Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung (GlobeNewswire)
Aug-09-24 12:00PM	Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's Why (Zacks) +5.54%
09:55AM	Wall Street Analysts Believe Corbus Pharmaceuticals (CRBP) Could Rally 54.24%: Here's is How to Trade (Zacks)
Aug-06-24 08:08AM	Corbus Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

PhDYuval Cohen

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ben Yong	Director	Sep 14 '26	Sale	7.84	2,000	15,683	9,383	Sep 15 04:59 PM
Saxena Nishant C	Chief Business Officer	Aug 11 '26	Buy	9.63	2,600	25,036	77,900	Aug 12 04:30 PM
Cohen Yuval	Chief Executive Officer	Aug 07 '26	Sale	10.08	17,000	171,396	157,316	Aug 10 04:30 PM
Moran Sean F.	Chief Financial Officer	Aug 07 '26	Sale	10.08	12,000	120,971	84,694	Aug 10 04:30 PM
Stifel, Nicolaus & Company, In	Officer	Aug 07 '26	Proposed Sale	10.08	12,000	120,971		Aug 07 04:23 PM
Stifel, Nicolaus & Company, In	Officer	Aug 07 '26	Proposed Sale	10.08	17,000	171,396		Aug 07 04:04 PM
Smethurst Dominic	Officer	Jul 27 '26	Proposed Sale	9.20	23,025	211,818		Jul 27 04:06 PM
Kung Winston	Director	Jun 10 '26	Sale	7.91	2,026	16,033	12,140	Jun 11 04:30 PM
Altmeyer Anne	Director	Jun 10 '26	Sale	7.91	2,412	19,088	7,579	Jun 11 04:30 PM
Jenkins John Kenneth	Director	Jun 10 '26	Sale	7.91	4,800	37,986	3,833	Jun 11 04:30 PM
Saxena Nishant C	Chief Business Officer	Jun 03 '26	Buy	7.58	9,000	68,220	75,300	Jun 03 05:36 PM
Saxena Nishant C	Chief Business Officer	Jun 02 '26	Buy	7.33	4,500	32,998	66,300	Jun 03 05:36 PM
Smethurst Dominic	Chief Medical Officer	Mar 02 '26	Sale	8.30	6,097	50,601	89,790	Mar 04 04:30 PM
Smethurst Dominic	Officer	Mar 02 '26	Proposed Sale	8.30	6,097	50,601		Mar 02 04:08 PM
Hodgson Ian	Chief Operating Officer	Feb 17 '26	Sale	7.38	847	6,253	51,080	Feb 18 04:32 PM
Moran Sean F.	Chief Financial Officer	Feb 13 '26	Sale	7.78	4,701	36,588	96,694	Feb 18 04:31 PM
Cohen Yuval	Chief Executive Officer	Feb 13 '26	Sale	7.78	13,871	107,952	174,316	Feb 18 04:30 PM
Cohen Yuval	Officer	Feb 13 '26	Proposed Sale	40.63	20,000	812,600		Feb 13 04:02 PM
Smethurst Dominic	Chief Medical Officer	Feb 03 '26	Sale	8.09	3,285	26,575	95,887	Feb 04 04:25 PM
Hodgson Ian	Chief Operating Officer	Feb 03 '26	Sale	8.09	2,415	19,537	51,927	Feb 04 04:24 PM
Cormorant Asset Management, LP	10% Owner	Dec 11 '25	Sale	11.46	30,029	344,012	2,344,971	Dec 15 04:18 PM
Cohen Yuval	Chief Executive Officer	Oct 24 '25	Option Exercise	4.26	18,660	79,492	156,847	Oct 27 04:23 PM
Cohen Yuval	Chief Executive Officer	Oct 27 '25	Option Exercise	4.26	8,973	38,225	147,160	Oct 27 04:23 PM
Cohen Yuval	Chief Executive Officer	Oct 24 '25	Sale	17.01	18,660	317,407	138,187	Oct 27 04:23 PM
Cohen Yuval	Chief Executive Officer	Oct 27 '25	Sale	17.14	8,973	153,797	138,187	Oct 27 04:23 PM
Moran Sean F.	Chief Financial Officer	Oct 24 '25	Option Exercise	4.26	12,981	55,299	86,294	Oct 27 04:22 PM
Moran Sean F.	Chief Financial Officer	Oct 24 '25	Sale	17.02	12,981	220,937	73,313	Oct 27 04:22 PM
Cohen Yuval	Officer	Oct 24 '25	Proposed Sale	17.01	27,633	469,977		Oct 24 04:18 PM
Moran Sean F.	Officer	Oct 24 '25	Proposed Sale	17.02	12,981	220,922		Oct 24 04:14 PM
Altmeyer Anne	Director	Oct 20 '25	Option Exercise	4.80	1,060	5,088	7,251	Oct 21 04:54 PM
Altmeyer Anne	Director	Oct 20 '25	Sale	20.50	1,060	21,730	6,191	Oct 21 04:54 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRBP

Corbus Pharmaceuticals Holdings Inc

Upgrade your Finviz experience